BioCentury
ARTICLE | Distillery Therapeutics

Cancer

April 3, 2018 6:16 PM UTC

Patient sample and mouse experiments suggest inhibiting TSLP signaling could help treat breast cancer. In tissue samples from breast cancer patients, levels of TSLPR in tumors were higher than in adjacent normal tissues. In a genetic mouse model and an orthotopic mouse model of metastatic breast cancer, systemic TSLP knockout decreased primary tumor size and metastasis to the lung compared with normal TSLP expression. In the genetic mouse model of metastatic breast cancer, an antibody targeting TSLP decreased primary tumor size compared with a control antibody. In the orthotopic mouse model of metastatic breast cancer, tumor-specific TSLPR knockout increased tumor cell death and decreased metastasis to the lung compared with normal TSLPR expression, and intranasal delivery of the anti-TSLP antibody decreased metastasis to the lung compared with a control antibody. Next steps include testing TSLP inhibitors in additional models of breast cancer (see “Targeting TSLP.” BioCentury Innovations (April 4, 2018))...